Moderna reported second-quarter revenue of $145 million, topping the $103 million analysts expected, while its Phase III Nova 301 study of norovirus vaccine mRNA-1403 missed statistical criteria for early success at an interim analysis and shares fell more than 3%. The company said the blinded trial will continue through another winter season with an added cohort, while it reaffirmed full-year guidance for up to 10% revenue growth and pointed to later-stage oncology catalysts including adjuvant melanoma data for intismeran autogene (mRNA-4157/V940).

Why It Matters To Oncology

• For oncology clinicians tracking drug discovery, Moderna's update underscores how non-oncology pipeline volatility can shape capital allocation, investor sentiment and development pace across the broader mRNA platform.

• The key oncology asset remains intismeran autogene, Moderna's personalized cancer vaccine co-developed with Merck, with pivotal adjuvant melanoma data potentially due later this year.

• Positive melanoma results could strengthen confidence that Moderna can extend its mRNA capabilities beyond infectious disease and COVID-19 into cancer treatment.

The Financials

• Second-quarter revenue was $145 million, versus $142 million a year earlier and above the $103 million Wall Street expected.

• Net loss was $800 million, an improvement of $43 million from the same quarter in 2025.

• R&D spending fell 7% to $651 million as several late-stage programs wound down.

• Moderna lowered full-year R&D expense guidance to about $2.9 billion from $3 billion and reiterated a full-year revenue outlook of up to 10% growth, split evenly between U.S. and international markets.

What They're Saying

• President Stephen Hoge said norovirus endpoint cases had not accrued as quickly as expected, so Nova 301 will continue through another winter season with an additional cohort while remaining blinded.

• Hoge said Moderna is building toward a broader, more diversified portfolio over the next three years while expanding its global commercial footprint.

• Barclays analysts said favorable melanoma data could bring meaningful credit to Moderna's broader cancer pipeline.

What's Next

• The near-term regulatory catalyst is the FDA's Aug. 5 decision on mFLUSIVA (mRNA-1010), Moderna's seasonal mRNA influenza vaccine.

• If approved, mFLUSIVA would become the first mRNA-based seasonal flu vaccine available in the U.S. and another step in diversification beyond COVID-19.

• For oncology, the bigger readout is expected melanoma data for mRNA-4157/V940, which could become a defining proof point for Moderna's cancer vaccine strategy.